Heron Therapeuti (HRTX) moved from Buy to Neutral at HC Wainwright & Co. on August 11, 2026, following a downgrade.
Zero of one firm active in the past 90 days rate the stock in the bullish tier. As of August 10, 2026, three analysts place the consensus mean at $2.04, the median at $2.04 and the range at $2.02 to $2.10.
Consensus Q4 FY2026 EPS is -$0.03, with revenue at $39.17 million. The next earnings report is on November 9, 2026 (confirmed).
